Abstract:
PURPOSE: A gene delivery system for transferring a target gene to cells is provided to enable stable delivery of the gene delivery system to an organism and to effectively suppress the expression of a specific disease gene. CONSTITUTION: A gene delivery system for transferring a target gene to cells is complexed by ionic interaction through mixing the target gene with polyethylene imine of Branched polyethylenimine cross-linked via disulfide bonds(ssPEI). The target gene is siRNA(small interfering RNA), an antisense molecule, an antagonist, ribozyme, an inhibitor, a peptide, or a small molecule. The target gene is siRNA which is specific to Akt gene. The target gene is fixed on a support. The support is a stent coated with hyaluronic acid or collagen on the surface.
Abstract:
PURPOSE: An intracellular gene delivery intracellular gene delivery containing cationic polymers and magnetic nanoaprticels is provided to treat various diseases using a gene. CONSTITUTION: An intracellular gene delivery composite contains cationic polymers of 1000-10,000 Da of molecular weight and magnetic nanoparticles. The cationic polymers are polyethylene imine(PEI), poly-L-lysine(PLL), or chitosan. The magnetic nanoparticles are thermally cross-linked superparamagnetic nanoparticles(TCL-SPION). The intracellular gene delivery composite is prepared by cross-linking of the cationic polymers and magnetic nanoparticles under the presence of -ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride(EDC) and N-hydroxysuccineimide(NHS).
Abstract:
A mannan-coated superparamagnetic iron oxide nanoparticle is provided, which enables specific flow of liver to kupffer cell and ensure stability of ferrofluid. A contrast media for diagnosing hepatism comprises a mannan coated superparamagnetic iron oxide nanoparticle. A method for manufacturing the nanoparticle comprises: a step of adding basic solution in iron chloride aqueous solution and dipping iron oxide nanoparticle; a step of oxidizing the iron oxide nanoparticle and producing storage solution; and a step of mixing mannan solution in the storage solution, stirring and coating.
Abstract:
The present invention relates to a conjugate prepared by conjugating mucosal vaccine adjuvants and allergen, and an allergen-specific immunotherapeutic agent; more specifically, to a conjugate prepared by using flagellin of vibrio vulnificus, which is a toll-like receptor-5 (TLR-5) drug and a vaccine adjuvant, and a hydrophilic multiple-bonded linker having a thiol group (-SH) of a dust mite extract; and a mucosal allergen-specific immunotherapeutic agent containing the same. [Reference numerals] (AA) Penh value (% relative to PBS); (BB) FlaB/HDM (10 μg) mixture; (CC) FlaB/HDM (3.5 μg) mixture; (DD) FlaB-HDM (3.5 μg) bonded body; (EE) Methacholine (mg/mL)
Abstract:
본 발명은 목적 유전자를 세포로 전달하기 위한 유전자 전달체에 관한 것으로, 보다 상세하게는 재내피화를 촉진하거나 평활근 세포의 증식을 억제하는 혈관 재협착 방지용 유전자 전달체 및 이의 제조방법에 관한 것이다. 본 발명에 따른 유전자 전달체는 목적 유전자가 이황화 결합을 통해 가교 결합된 폴리에틸렌이민(Branched polyethylenimine cross-linked via disulfide bonds; ssPEI)과 복합체화(complexed)됨으로써 유전자 전달체의 안정적인 생체로의 전달이 가능하며, 기존의 사용하는 고분자물질로 야기되는 혈전이나 염증 유발 등의 문제를 해결 뿐 아니라 많은 양의 목적 유전자 특히 siRNA와의 결합이 가능하여 특정 질병 유전자의 발현을 효율적으로 억제할 수 있는 장점이 있다. 뿐만 아니라 본 발명에 따른 유전자 전달체는 히알루론산(hyaluronic acid)이 코팅된 스텐트상에 목적 유전자를 고정화시킴으로써 유전자를 세포내로 전달 효율이 매우 높은 장점이 있으며, 정상세포에 대한 독성을 현저히 줄일 수 있는 장점이 있다.
Abstract:
본 발명은 목적 유전자를 세포로 전달하기 위한 유전자 전달체에 관한 것으로, 상기 본 발명에 따른 유전자 전달체는 질병세포 또는 조직에 목적 유전자를 안정적으로 전달하고, 표적세포에 대한 선택성을 충분히 나타내면서 정상세포에의 독성을 현저히 줄이고, 지속적인 목적 유전자의 전달이 가능하게 하는 장점 뿐 아니라 일반 저분자량의 유전자 전달체 보다 질병 조직에 대한 선택성이 높아 더 많은 양이 표적 세포 또는 조직에 축적되어, 획기적인 치료 작용을 발휘할 수 있는 장점이 있다.
Abstract:
PURPOSE: A gene delivery system for transferring a target gene to cells is provided to stably transfer the target gene to disease cells or tissues and to reduce toxicity in normal cells. CONSTITUTION: A gene delivery system for transferring a target gene to cells contains: biodegradable polyester amine nanofibers prepared by electrospinning a polymer solution containing polyethyleneimine(PEI) and polycaprolactone(PCL); and a target gene fixed on the nanofiber. The target gene is complexed with branched polyethylenimine cross-linked via disulfide bonds(ssPEI). The target gene is an angiogenic factor gene. A pharmaceutical composition for angiogenesis contains the gene delivery system. The pharmaceutical composition is used for preventing or treating coronary artery disease.